Andere Sprachen Ultragenyx Pharmaceutical Inc.

Aktien

A1XCY0

US90400D1081

RARE

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
44,24 ^USD	+0,89 %		+4,41 %	-7,49 %

23.04.	ULTRAGENYX PHARMACEUTICAL INC. : erhält Kaufen-Rating von RBC Capital Markets	ZM
15.04.	Transcript : Ultragenyx Pharmaceutical Inc. - Special Call

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update	25.04.
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(4) - April 19, 2024	22.04.
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	19.04.
Health Care Ticks Down Amid Rotation From Rate-Sensitive Sectors -- Health Care Roundup	15.04.
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology 2024 Annual Meeting	15.04.
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome	15.04.
Ultragenyx Says Data From Phase 1/2 Trial of GTX-102 to Treat Angelman Syndrome Showed 'Meaningful Improvement'	15.04.
Sector Update: Health Care Stocks Advance Premarket Monday	15.04.
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102	15.04.
Ultragenyx Pharmaceutical Inc. Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102	15.04.
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome	12.04.
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting	12.04.
Ultragenyx Reports Inducement Grant under Nasdaq Listing Rule 5635(4)	25.03.
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	22.03.
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	22.03.
Ultragenyx Pharmaceutical Insider Sold Shares Worth $574,644, According to a Recent SEC Filing	12.03.
Ultragenyx to Participate at Investor Conferences in March	27.02.
Ultragenyx Reports Inducement Grant under Nasdaq Listing Rule 5635(4)	26.02.
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	23.02.
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	23.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Ultragenyx Pharmaceutical Inc.

Aktien

A1XCY0

US90400D1081

RARE

Andere Sprachen

Filter